Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Bioequivalence Study With Two Tablet Strengths of the Final Market Image (FMI) Sitagliptin/Metformin Fixed Dose Combination (FDC) Tablet

NCT01093794 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.

NCT NCT01093794
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01093794 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Bioequivalence Study With Two Tablet Strengths of the Final Market Image (FMI) Sitagliptin/Metformin Fixed Dose Combination (FDC) Tablet
Lead sponsor
Merck Sharp & Dohme LLC
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2010
Completion date
June 30, 2010
Enrollment
28 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes